An adjusted indirect treatment comparison (ITC) of enzalutamide (ENZ) versus docetaxel (DOC) for metastatic hormone-sensitive prostate cancer (mHSPC)

被引：0
|
作者：
Ohlmann, Carsten [1 ]
Armstrong, Andrew [2 ]
Gratzke, Christian [3 ]
Sugg, Jennifer [4 ]
Ganguli, Arijit [4 ]
Dornstauder, Eugen [5 ]
Gross-Langenhoff, Marco [5 ]
Brauner, Reinhard [5 ]
Stenzl, Arnulf [6 ]
机构：
[1] Johanniter Krankenhaus Bonn, Bonn, Germany
[2] Duke Univ, Durham, NC USA
[3] Univ Klinikum Freiburg, Freiburg, Germany
[4] Astellas, Northbrook, IL USA
[5] Astellas Pharma GmbH, Munich, Germany
[6] Eberhard Karls Univ Tubingen, Tubingen, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2022年 / 45卷 / SUPPL 3期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
881
引用
收藏
页码：109 / 109
页数：1
相关论文
共 50 条
  • [1] Indirect comparison of abiraterone acetate and docetaxel for treatment of metastatic "hormone-sensitive" prostate cancer
    Feyerabend, S.
    Saad, F.
    Li, T.
    Ito, T.
    Diels, J.
    Van Sanden, S.
    De Porre, P.
    Roiz, J.
    Abogunrin, S.
    Fizazi, K.
    ANNALS OF ONCOLOGY, 2017, 28
  • [2] Recent developments in the treatment of metastatic hormone-sensitive prostate cancer (mHSPC)
    Schwentner, Christian
    AKTUELLE UROLOGIE, 2022, 53 (01) : 31 - 36
  • [3] Docetaxel, abiraterone, enzalutamide, apalutamide in patients with metastatic hormone-sensitive prostate cancer
    Talwar, Harkirat Singh
    INDIAN JOURNAL OF UROLOGY, 2021, 37 (03) : 288 - 290
  • [4] Efficacy of bi-weekly docetaxel in hormone-sensitive metastatic prostate cancer (mHSPC).
    Lombana Quinonez, Milton Alberto
    Milena Torres, Ana
    Gonzalez, Guido
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [5] TITAN study: evaluation of apalutamide in patients with metastatic hormone-sensitive prostate cancer - Treatment of metastatic hormone-sensitive prostate cancer (mHSPC)
    Merseburger, Axel S.
    Suttmann, Henrik
    AKTUELLE UROLOGIE, 2021, 52 (02) : 155 - 160
  • [6] Comparison of outcomes with docetaxel or ARPI combination therapy for metastatic hormone-sensitive prostate cancer (mHSPC) by volume of disease
    Schoen, Martin W.
    Etzioni, Ruth Douglas
    Luo, Suhong
    Candelieri, Danielle
    Fedele, Nicholas
    Baxi, Priya
    Pickett, Carley
    Riekhof, Forest
    Ingram, Kara
    Karunanandaa, Krishny
    Govindan, Srinivas
    Cheranda, Nina
    Knoche, Eric Marshall
    Montgomery, Robert Bruce
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [7] Docetaxel for hormone-sensitive metastatic prostate cancer
    Baker, Holly
    LANCET ONCOLOGY, 2015, 16 (09): : E432 - E432
  • [8] Management of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): an Evolving Treatment Paradigm
    Weiner, Adam B.
    Nettey, Oluwarotimi S.
    Morgans, Alicia K.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2019, 20 (09)
  • [9] Management of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): an Evolving Treatment Paradigm
    Adam B. Weiner
    Oluwarotimi S. Nettey
    Alicia K. Morgans
    Current Treatment Options in Oncology, 2019, 20
  • [10] A systematic review: Are the findings of indirect treatment comparisons (ITCs) in metastatic hormone-sensitive prostate cancer (mHSPC) consistent?
    Shore, Neal D.
    Morgans, Alicia K.
    Paracha, Noman
    Hodgkinson, Sarah
    Eichinger, Christian
    Millar, Craig
    Chen, Stephanie
    Boegemann, Martin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 324 - 324
12345